A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in Major Depressive Disorder (TERPSIS STUDY)
Latest Information Update: 02 Aug 2024
At a glance
- Drugs TAK 041 (Primary)
- Indications Anhedonia; Major depressive disorder
- Focus Therapeutic Use
- Acronyms TERPSIS STUDY
- Sponsors Neurocrine Biosciences
Most Recent Events
- 09 Nov 2023 Primary endpoint has not been met. (Change in anhedonia severity, as measured by change in Dimensional Anhedonia Rating Scale (DARS) score from baseline to Day 57)
- 09 Nov 2023 Results published in the Media Release
- 15 Sep 2023 Status changed from active, no longer recruiting to completed.